Top 50 Life Science VC Funds & Investors in Belgium (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Meusinvest (Noshaq)
VC Fund
|
11 | Belgium, France, Germany | Series A, Seed, Venture - Series Unknown | Biotechnology, Health Care, Medical | $137k–$16M |
|
PMV
VC Fund
|
6 | Belgium, United States, The Netherlands | Seed, Series A, Series B | Software, Biotechnology, Health Care | $1M–$43M |
|
Qbic Fund
VC Fund
|
5 | Belgium, France, The Netherlands | Seed, Series A, Venture - Series Unknown | Biotechnology, Software, Health Care | $1.4M–$34M |
|
Theodorus III
VC Fund
|
4 | Belgium, Canada, France | Series A, Seed, Venture - Series Unknown | Health Care, Biotechnology, Software | $67k–$41M |
|
Limburgse Reconversie Maatschappij
VC Fund
|
3 | Belgium, The Netherlands, United States | Seed, Venture - Series Unknown | Information Technology, Software, Biotechnology | $658k–$11M |
|
S.R.I.W.
VC Fund
|
3 | Belgium, United States, Spain | Venture - Series Unknown, Series A | Health Care, Biotechnology, Manufacturing | $422k–$32M |
|
Innovation Fund
VC Fund
|
3 | Belgium, France, Luxembourg | Seed, Venture - Series Unknown, Series A | Health Care, Manufacturing, Chemical | $318k–$8.8M |
|
Sambrinvest
VC Fund
|
3 | Belgium, France, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $544k–$49M |
|
Mérieux Equity Partners
VC Fund
|
3 | France, United States, Spain | Series A, Private Equity, Venture - Series Unknown | Health Care, Biotechnology, Medical | $5.7M–$150M |
|
VIB
VC Fund
|
2 | Belgium, Brazil, Denmark | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $3.1M–$84M |
|
SFPI-FPIM
VC Fund
|
2 | Belgium, United States, The Netherlands | Series B, Venture - Series Unknown, Series A | Health Care, Biotechnology, Medical | $2.7M–$75M |
|
New Science Ventures
VC Fund
|
2 | United States, United Kingdom, Belgium | Series B, Series A, Series D | Biotechnology, Health Care, Medical | $4M–$52M |
|
Innovation Industries
VC Fund
|
2 | The Netherlands, Belgium, Germany | Series A, Seed, Series B | Semiconductor, Biotechnology, Manufacturing | $552k–$65M |
|
UCB Ventures
VC Fund
|
2 | United States, Belgium, Spain | Series A, Series B, Venture - Series Unknown | Biotechnology, Health Care, Medical | $7M–$135M |
|
V-Bio Ventures
VC Fund
|
2 | Belgium, France, United States | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $3.1M–$88M |
|
Galapagos
VC Fund
|
1 | United States, France, Belgium | Seed, Series A, Series C | Biotechnology, Health Care, Life Science | $52M–$125M |
|
Seventure Partners
VC Fund
|
1 | France, United States, Germany | Series A, Series B, Seed | Biotechnology, Software, Health Care | $1.1M–$63M |
|
Luma Group
VC Fund
|
1 | United States, Belgium | Series A, Series B, Series C | Biotechnology, Health Care, Biopharma | $40M–$125M |
|
the SRIW Life Sciences
VC Fund
|
1 | Belgium | Series A, Series B | Biotechnology, Medical, Biopharma | $22M–$23M |
|
Smedvig
VC Fund
|
1 | Belgium, Romania, South Africa | Series A, Series C | Mining, Medical, Software | |
|
Capricorn Partners
VC Fund
|
1 | Belgium, The Netherlands, United States | Series A, Series B | Biotechnology, Health Care, Software | $3.3M–$45M |
|
Fund+
VC Fund
|
1 | Belgium, United States, Spain | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $11M–$401M |
|
Korys
VC Fund
|
1 | Belgium, The Netherlands, Germany | Series B, Series A, Venture - Series Unknown | Biotechnology, Renewable Energy, Software | $4.4M–$50M |
|
Longwood Fund
VC Fund
|
1 | United States, United Kingdom, Italy | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $16M–$141M |
|
Qbic
VC Fund
|
1 | Belgium | Seed, Series B | Health Care, Biotechnology, AgTech | $3.7M–$12M |
|
Vives Louvain Technology Fund
VC Fund
|
1 | Belgium, France, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $156k–$125M |
|
6K Venture Capital
VC Fund
|
1 | Panama, Belgium | Seed, Series A | Gaming, Medical, Health Care | |
|
OBI SA
VC Fund
|
1 | Belgium | Venture - Series Unknown | Life Science, Biotechnology, Health Diagnostics | |
|
Forbion Capital Partners
VC Fund
|
1 | United States, United Kingdom, The Netherlands | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $16M–$180M |
|
BioGeneration Ventures
VC Fund
|
1 | The Netherlands, United States, Belgium | Series A, Seed | Biotechnology, Therapeutics, Health Care | $1.1M–$86M |
|
VIVES Funds
VC Fund
|
1 | Belgium, France, Switzerland | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $2.9M–$165M |
|
Finchley Healthcare Ventures
VC Fund
|
1 | United States, Canada, Belgium | Series B, Seed, Series A | Biotechnology, Biopharma, Health Care | $67M–$120M |
|
Novo Holdings
VC Fund
|
1 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9.5M–$135M |
|
European Circular Bioeconomy Fund
VC Fund
|
1 | Germany, France, The Netherlands | Series B, Series A, Venture - Series Unknown | Biotechnology, AgTech, Agriculture | $5.9M–$45M |
|
Samsara BioCapital
VC Fund
|
1 | United States, United Kingdom, Canada | Series B, Post-IPO Equity, Series A | Biotechnology, Health Care, Therapeutics | $33M–$200M |
|
Industrya
VC Fund
|
1 | France, Belgium | Seed, Series A, Venture - Series Unknown | Industrial, Manufacturing, Logistics | $946k–$6.7M |
|
European Investment Bank
VC Fund
|
1 | France, Germany, Italy | Debt Financing, Post-IPO Debt, Venture - Series Unknown | Energy, Biotechnology, Health Care | $8.7M–$587M |
|
Opdorp Finance BVBA
VC Fund
|
1 | Belgium | Series A | Software, Analytics, Life Science | |
|
Regeneron Ventures
VC Fund
|
1 | United States, Belgium | Series B, Series A, Series C | Biotechnology, Health Care, Life Science | $40M–$175M |
|
Nausicaa Ventures
VC Fund
|
1 | Belgium | Series B, Series C, Venture - Series Unknown | Software, CRM, Big Data | $9.4M–$10M |
|
Sofinnova Investments
VC Fund
|
1 | United States, France, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Therapeutics | $7.3M–$150M |
|
Newton Biocapital
VC Fund
|
1 | Belgium, Japan, France | Series A, Venture - Series Unknown, Seed | Biotechnology, Medical, Pharmaceutical | $1.3M–$84M |
|
Fonds Vives II (University of Louvain, UCL)
VC Fund
|
1 | Belgium, United States | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $6.6M–$75M |
|
Balyasny Asset Management
VC Fund
|
1 | United States, China, Latvia | Post-IPO Equity, Series A, Series D | Biotechnology, Health Care, Biopharma | $6.1M–$225M |
|
Flanders Future Techfund
VC Fund
|
1 | Belgium, The Netherlands | Seed, Series A, Venture - Series Unknown | Medical, Biotechnology, Clinical Trials | $2.7M–$30M |
|
Ifoghas Investments
VC Fund
|
1 | Belgium | Series A | Medical, Health Care, Life Science | |
|
Nivelinvest
VC Fund
|
1 | Belgium, United States | Series A, Seed, Series B | Biotechnology, iOS, Energy | $6.6M–$32M |
|
Novo Nordisk
VC Fund
|
1 | United States, Denmark, Canada | Corporate Round, Series A, Series C | Biotechnology, Health Care, Therapeutics | $5M–$57M |
|
invest.bw
VC Fund
|
1 | Belgium, United States | Seed, Pre-Seed, Series A | Biotechnology, Electronics, Health Care | $2.9M–$43M |
|
Epimède
VC Fund
|
1 | Belgium, The Netherlands | Series B, Series C, Series D | Biotechnology, Medical, Health Care | $12M–$26M |
| Access all 71 VC funds in Belgium Life Science startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 82
- Round size: Seed $137k–$6M; Series A $3.6M–$16M; Venture - Series Unknown $2M–$16M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Do and dare company
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 161
- Round size: Seed $1M–$4.1M; Series A $3M–$40M; Series B $6.6M–$43M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Logibot — Logibot is a European, software-first, hardware-agnostic AI platform that enables logistics and industrial operators to simulate, deploy, and operate human-like robotic labor inside existing intralogistics facilities, without vendor lock-in and without rebuilding the warehouse. Most warehouse automation projects fail because they assume greenfield sites or commit operators to one robot vendor. Logibot takes a different approach. Operators start with Logibot.Data to quantify manual work and score automation feasibility. Logibot.Simulate runs split tests on multiple robot configurations in digital simulation, before any hardware decision is made. Logibot.Train prepares a general vision-language model for specific logistics tasks in five stages. Logibot.Control stages the introduction of robotic labor into live operations. Logibot.Watch provides real-time monitoring, teleoperation, and continuous improvement. Logibot serves 3PLs, CEP operators, postal operators, and industrial logistics teams. Headquartered in Belgium, operating across the EU. NVIDIA Inception member. Beam Berlin portfolio company.
- Borro — Cashless deposit system
- SpectaCell — SpectaCell is a Belgian life sciences and biotechnology company that develops next-generation cell therapy analytics.Spun out of a collaborative research effort between imec, VIB, and Ghent University (UGent),
The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Our investment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support. In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Belgium, France, The Netherlands
Investor stats
- Total investments: 62
- Round size: Seed $1.4M–$7.4M; Series A $1.6M–$34M; Venture - Series Unknown $2.2M–$9.4M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $54M in 2022
Portfolio highlights
- Firecell — Firecell is a Telecommunications Industry.
- Eyeo — eyeo revolutionizes imaging with color splitter sensors. Capture sharper, brighter images in low light using optical waveguide innovation, discover how it works
- Sightera Biosciences — Patient-derived organoids of treatment-resistant disease, robotic screening at scale and AI-guided molecular design in one closed loop.
Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Belgium, Canada, France
Investor stats
- Total investments: 22
- Round size: Seed $67k–$18M; Series A $1.3M–$41M; Venture - Series Unknown $3.6M–$20M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Icentia — Icentia provides a range of innovative medical tests for healthcare institutions. They are able to offer valuable solutions for major problems in the field of medical testing.
- Simmunome AI — We use AI to create accurate, comprehensive disease models using multi-omic data to determine the probability of success of a drug. Our clinical trial simulations allow you to gain insights, make go/no-go decisions, and de-risk your pipeline, getting you to market faster and reducing your R&D co
- Ability biologics — Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
Oxygen for growth - LRM
Show more...Investment focus
- Industry: Information Technology, Software, Biotechnology
- Stage:Seed, Venture - Series Unknown
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 98
- Round size: Seed $658k–$5.2M; Venture - Series Unknown $1.4M–$11M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Monsana — Monsana's AI-powered platform empowers both patients and healthcare professionals in their search for the perfect clinical trial. Each eligibility criterion is validated based on your unstructured textual medical records, allowing highly accurate matching with experimental treatments.
- ADLC — ADLC employs drone technology to deliver logistics services, allowing businesses to implement drone-based solutions without having to manage them in-house. The company is focused on enhancing last-mile delivery in maritime and offshore environments. ADLC now conducts drone delivery services in the Port of Antwerp in collaboration with SGS, atesting and certification company, and works with companies such as BASF. Its drones have reduced delivery times and environmental effect, boosting efficiency sixfold and lowering CO2 emissions by up to 80% for petrochemical sample deliveries.
- Optiflux — Optiflux automatiseert het bewaarbeheer van vers fruit met slimme AI & vision-technologie. Minder verlies, meer winst voor teler & handelaar.
The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the Société Régionale d’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Venture - Series Unknown, Series A
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 111
- Round size: Series A $422k–$32M; Venture - Series Unknown $2.7M–$27M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Univercells — Mix parlay, atau lebih dikenal sebagai parlay bola atau hanya parlay, merupakan taruhan judi bola online yang menggabungkan minimal 2 hingga 10 tim pertandingan sepak bola menjadi 1 tiket taruhan.
- Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
- Santero Therapeutics — This is the homepage of the website
Chemical, Advanced Materials, Cosmetics, Recycling, CleanTech, Plastics and Rubber Manufacturing, Nanotechnology, Biosciences
Show more...Investment focus
- Industry: Health Care, Manufacturing, Chemical
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Belgium, France, Luxembourg
Investor stats
- Total investments: 31
- Round size: Seed $318k–$6M; Series A $2.3M–$5M; Venture - Series Unknown $1.1M–$8.8M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
- Fyteko — For a more sustainable agriculture
- Graftys — Graftys, an Aix-en-Provence, France-based early stage company focused on advanced bone biologics.
Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: Belgium, France, Spain
Investor stats
- Total investments: 41
- Round size: Seed $544k–$24M; Series A $1M–$49M; Series B $4.4M–$45M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Brenus Pharma — Brenus Pharma develops off-the-shelf, next-generation in vivo immunotherapies designed to unlock the immune response against solid tumors.
- Vertical Compute — Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently manages more than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Private Equity, Venture - Series Unknown
- Geography: France, United States, Spain
Investor stats
- Total investments: 54
- Round size: Series A $5.7M–$23M; Private Equity $23M–$150M; Venture - Series Unknown $12M–$90M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely actively investing — fresh fund, raised $383M in 2026
Portfolio highlights
- HighLife — HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.
- Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Strategic research in on life sciences and biotechnology
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: Belgium, Brazil, Denmark
Investor stats
- Total investments: 29
- Round size: Seed $3.1M–$11M; Series A $6.8M–$84M; Series B $4.7M–$65M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
- SpectaCell — SpectaCell is a Belgian life sciences and biotechnology company that develops next-generation cell therapy analytics.Spun out of a collaborative research effort between imec, VIB, and Ghent University (UGent),
- Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Venture - Series Unknown, Series A
- Geography: Belgium, United States, The Netherlands
Investor stats
- Total investments: 42
- Round size: Series A $4.3M–$49M; Series B $12M–$75M; Venture - Series Unknown $2.7M–$51M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- Cohabs — We create sustainable & community-driven shared homes around the world for young workers and interns. Join our community.
- Axelera AI — Axelera AI is a company that delivers purpose-built hardware and software platforms designed to accelerate artificial intelligence tasks, particularly in edge computing. The company's flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions.This platform has been recognized for its innovation, notably being named a CES® 2024 Innovation Awards Honoree.Incubated in 2019 by the emerging technologies leader Bitfury and joined by the leading nano-technology group imec in early 2020, Axelera AI launched as a new company in 2021. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, Axelera AI has R&D offices in Belgium, Switzerland, and Italy. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.
- Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.
New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companies using science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series D
- Geography: United States, United Kingdom, Belgium
Investor stats
- Total investments: 92
- Round size: Series A $4M–$49M; Series B $8M–$52M; Series D $5M–$38M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — raised $24M in 2021
Portfolio highlights
- Trellis Bioscience — Trellis Bioscience is developing native human antibodies to disrupt bacterial biofilms and address difficult-to-treat infections.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
- One Silicon Chip Photonics — Explore OSCP photonic and MEMS IMUs for GNSS-denied applications. Compare products, review integration resources, and contact our team about an evaluation.
Innovation Industries is a Dutch venture capital fund investing in impactful deep tech, focusing on sustainability, scalability, and ESG-aligned companies.
Show more...Investment focus
- Industry: Semiconductor, Biotechnology, Manufacturing
- Stage:Series A, Seed, Series B
- Geography: The Netherlands, Belgium, Germany
Investor stats
- Total investments: 86
- Round size: Seed $552k–$9.5M; Series A $12M–$47M; Series B $12M–$65M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely still investing — raised $215M in 2023
Portfolio highlights
- Euclyd — Euclyd develops AI infrastructure designed to make advanced AI computing more efficient and scalable. Its platform combines programmable ASIC compute, processor-memory co-design, and system-level optimization to address power, memory, and infrastructure constraints. Its products include craftwerk, an agentic AI silicon platform, and CWS 32, an AIcomputing system focused on low-power exascale performance. Euclyd also develops silicon architecture, systems, firmware, compilers, and runtime software for AI infrastructure.
- Morphotonics — Morphotonics develops large-area nanoimprint lithography technology for scalable AR waveguide manufacturing, nano-optics, and advanced photonics applications.
- VitalFluid — We empower growers to adopt plasma technology as a natural, residue-free alternative to chemical fungicides. We develop innovative, easy-to-use technology to produce Plasma Activated Water (PAW), using only water, air and electricity.
UCB Ventures is a €150 million strategic corporate venture fund
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: United States, Belgium, Spain
Investor stats
- Total investments: 22
- Round size: Series A $7M–$75M; Series B $9.4M–$135M; Venture - Series Unknown $12M–$42M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- ViaNautis — Precision Solutions
- SonoThera — Explore therapeutic ultrasound for non-invasive, targeted genetic medicine delivery that improves precision and biodistribution. Learn more.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: Belgium, France, United States
Investor stats
- Total investments: 45
- Round size: Seed $3.1M–$50M; Series A $6.9M–$70M; Series B $12M–$88M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — raised $131M in 2021
Portfolio highlights
- Animab — Animal Health Company
- RootWave — RootWave is an electronics company that develops tools that kill weeds it enables farmers to control weeds on their farm. Its technology is an alternative substitute for herbicides and other weed control chemicals. The company was founded in 2012 and headquartered in Warwickshire, United Kingdom.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
Lakefront Biotherapeutics is a clinical-stage biotech advancing immunology and inflammation programs, anchored by gamgertamig for autoimmune diseases.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Seed, Series A, Series C
- Geography: United States, France, Belgium
Investor stats
- Total investments: 5
- Round size: Series A $52M–$125M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Terratis — Terratis is a French company that uses the Sterile Insect Technique (SIT) to reduce the populations of tiger mosquitoes and agricultural pests. Their mission is to diminish harmful insect populations effectively on a large scale using a scientific, innovative, ecological, and efficient approach.
- Third Arc Bio — Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune diseases.
- Coultreon Biopharma — Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune disease. Our pipeline targets SIK3 to deliver transformative therapies where unmet need remains high.
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion. Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion under management as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations. Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors. The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B, Seed
- Geography: France, United States, Germany
Investor stats
- Total investments: 274
- Round size: Seed $1.1M–$4.7M; Series A $3.2M–$28M; Series B $3.4M–$63M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
- Presto Engineering — We enable companies imagine and implement microelectronics solutions in high-value markets such as Industrial, Automotive, Communication and Medical.
- Kainova Therapeutics — Domain Therapeutics is a biopharmaceutical company focused on GPCR in immuno-oncology. Discover more than you think on our innovative cancer treatments tackling GPCR mediated-immunosuppression
Fueling the future of human health and longevity with cutting edge innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Biopharma
- Stage:Series A, Series B, Series C
- Geography: United States, Belgium
Investor stats
- Total investments: 5
- Round size: Series A $40M–$125M; Series B $55M–$93M
- Lead/follow: 60% lead, 40% follow
Portfolio highlights
- Curve Biosciences — Whole-Body Intelligence to resolve chronic diseases.
- Coultreon Biopharma — Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune disease. Our pipeline targets SIK3 to deliver transformative therapies where unmet need remains high.
- Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
the SRIW Life Sciences
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Series A, Series B
- Geography: Belgium
Investor stats
- Total investments: 3
- Round size: Series B $22M–$23M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Venture Capital firm based in London. We help enable business funding though capital investment. In turn, that funds and drives business growth as exceptional speed. Visit our site to find out how our proven model of business investment can help your start up.
Show more...Investment focus
- Industry: Mining, Medical, Software
- Stage:Series A, Series C
- Geography: Belgium, Romania, South Africa
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Druid AI — DRUID is an AI platform that allows companies to automate processes by designing and deploying UiPath RPA integrated chatbot virtual assistants.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
- Sedibelo Resources — Sedibelo Resources is a developing producer of platinum group metals (PGMs), is active in the acquisition, exploration for, and development and operation of deposits
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series A, Series B
- Geography: Belgium, The Netherlands, United States
Investor stats
- Total investments: 122
- Round size: Series A $3.3M–$18M; Series B $5.3M–$45M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely actively investing — fresh fund, raised $53M in 2025
Portfolio highlights
- HighLife — HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.
- Endo Tools Therapeutics — Endo Tools Therapeutics is dedicated to the development of innovative devices that provide therapeutic interventions for gastric conditions
- Delft Advanced Biorenewables — We enable the bio-economy by improving the productivity of fermentations with our in-situ product recovery (ISPR) technology.
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: Belgium, United States, Spain
Investor stats
- Total investments: 35
- Round size: Series A $12M–$47M; Series B $22M–$125M; Series C $11M–$401M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Korys is the name chosen by the Colruyt family for their investment structure. The name Korys is derived from the Latin word for hazelnut tree – Corylus - which is at the origin of the Colruyt name.Their multi-disciplinary approach enables us to create a well-balanced, diversified portfolio of listed stocks and bonds, private equity funds, anddirect participations in small and medium-sized companies. Through their investments, they aim to make a positive impact on people and the planet, while generating attractive returns. A “three P” approach (People, Planet, Profit) forms the cornerstone of their investment strategy. They invest for the long term, as they realize that it takes time to achieve the sustainable impact they are aiming for. They focus their investments in sectors in which they have built substantial expertise as a team: Cleantech, consumer goods & retail and life sciences.
Show more...Investment focus
- Industry: Biotechnology, Renewable Energy, Software
- Stage:Series B, Series A, Venture - Series Unknown
- Geography: Belgium, The Netherlands, Germany
Investor stats
- Total investments: 48
- Round size: Series A $4.4M–$13M; Series B $6.6M–$50M; Venture - Series Unknown $4.7M–$39M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Entrix — Entrix is an optimisation and trading platform for grid-scale battery storage that accelerates the transition towards a clean energy future. Our mission is to enable the most effective use of green energy and to ensure the reliability of the future energy system. We provide state-of-the-art technology and services to both asset owners and potentialinvestors across the globe.
- OroraTech — From safeguarding forests and ecosystems to protecting communities and critical assets, OroraTech's advanced technology and reliable insights address challenges, mitigate risks, and drive meaningful impact.
- Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
Investing where Discovery becomes Patient Care As life science venture investors, industry connectors, and company founders, Longwood Fund identifies and
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Italy
Investor stats
- Total investments: 81
- Round size: Series A $16M–$100M; Series B $30M–$141M; Series C $17M–$100M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $158M in 2023
Portfolio highlights
- Neomorph — We engineer neomorphic protein surfaces to unlock targeted protein degradation.
- Coultreon Biopharma — Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune disease. Our pipeline targets SIK3 to deliver transformative therapies where unmet need remains high.
- Khartis Therapeutics — Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases. The company focuses on discovering and developing drug candidates intended to address chronic conditions and immune-mediated diseases.
Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.
Show more...Investment focus
- Industry: Health Care, Biotechnology, AgTech
- Stage:Seed, Series B
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Seed $3.7M–$11M; Series B $8.2M–$12M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
- Axithra — Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.
- Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: Belgium, France, United States
Investor stats
- Total investments: 27
- Round size: Seed $1.6M–$7.3M; Series A $156k–$49M; Series B $4.7M–$125M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — raised $38M in 2020
Portfolio highlights
- BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
6K Venture Capital operates as a venture capital firm.
Show more...Investment focus
- Industry: Gaming, Medical, Health Care
- Stage:Seed, Series A
- Geography: Panama, Belgium
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Rise Of Defenders — Rise of Defenders is a very interesting Metaverse NFT game, you can use your creativity and tactical thinking to become an excellent player and receive extremely attractive rewards.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
OBI SA
Show more...Investment focus
- Industry: Life Science, Biotechnology, Health Diagnostics
- Stage:Venture - Series Unknown
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Diagenode — Diagenode is an international life sciences company that develops and commercializes innovative instruments and reagents systems for life science research and molecular diagnostics. Founded in 2003 in Liege (Belgium), Diagenode is a global company, with headquarters in Liege, Belgium and Sparta, NJ, USA. Diagenode also has a local sales office inthe United Kingdom to better serve this specific country.Diagenode's customers include leading epigenetics researchers, academic institutions, high-profile genome centers and core labs, life sciences tools companies, molecular diagnostics players, and pharmaceutical and biotechnology companies.Epigenetics Division
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 229
- Round size: Series A $19M–$180M; Series B $16M–$155M; Series C $22M–$123M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fresh fund, raised $606M in 2026
Portfolio highlights
- OMass Therapeutics — OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets.
- Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Shaping new life-science ventures.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Health Care
- Stage:Series A, Seed
- Geography: The Netherlands, United States, Belgium
Investor stats
- Total investments: 68
- Round size: Seed $1.1M–$50M; Series A $6M–$86M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $172M in 2021
Portfolio highlights
- Dualyx — Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
- RougeTx — RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding.
- Noviogendix Holding — NovioGendix, a privately-held molecular diagnostics company focused on the development of a non-invasive liquid biopsy test for prostate cancer. NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnosticassays for uro-oncological practice. NovioGendix has a range of diagnostic tests for prostate, bladder, kidney and other urologic cancers in various stages of development. Commencing activities in 2008 as a Radboud University Medical Center (Radboudumc) spin-off company, NovioGendix has a standing cooperation with various Radboudumc departments. The main shareholders of NovioGendix include BioGeneration Ventures, and Participatiemaatschappij Oost Nederland.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!VIVES is a seed capital fund initiated by UCLouvain which invests in companies developing disruptive innovations with a positive societal impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: Belgium, France, Switzerland
Investor stats
- Total investments: 11
- Round size: Seed $2.9M–$5.5M; Series A $18M–$165M; Series B $34M–$132M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Bionyra — Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases.
- Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Finchley Healthcare Ventures is an investment firm invest in venture capital funds specializing in life sciences, leveraging their expertise and network to access a diverse range of investment opportunities.
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Health Care
- Stage:Series B, Seed, Series A
- Geography: United States, Canada, Belgium
Investor stats
- Total investments: 4
- Round size: Series B $67M–$120M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Coultreon Biopharma — Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune disease. Our pipeline targets SIK3 to deliver transformative therapies where unmet need remains high.
- Triana Biomedicines — Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.
- Cartography Biosciences — Cartography is shaping a world in which cancer immunotherapies are designed around and directed toward the safest and most effective targets.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 409
- Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
- SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
The specialist VC for a regenerative economy
Show more...Investment focus
- Industry: Biotechnology, AgTech, Agriculture
- Stage:Series B, Series A, Venture - Series Unknown
- Geography: Germany, France, The Netherlands
Investor stats
- Total investments: 29
- Round size: Series A $5.9M–$19M; Series B $10M–$45M; Venture - Series Unknown $8.7M–$20M
- Lead/follow: 66% lead, 34% follow
- Last fund: Likely still investing — raised $339M in 2022
Portfolio highlights
- Wakuli — It's called specialty coffee. Roasted lighter to enhance all the exciting flavours. To really taste them it's important to drink fresh. That's why we send our mailbox-friendly coffee within one week after roasting. And always with a better price for the farmers - thanks to you.
- Reduced — Reduced develops natural flavor enhancers from upcycled produce.
- foodforecast — AI supported solution to reduce food waste.
Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotes biotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Post-IPO Equity, Series A
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 189
- Round size: Series A $33M–$150M; Series B $35M–$170M; Post-IPO Equity $40M–$200M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely actively investing — fresh fund, raised $98M in 2025
Portfolio highlights
- Abcuro — The determination of people living with inclusion body myositis inspires our work and strengthens our resolve to advance precision therapies with the potential to change what's possible.
- Gossamer Bio — Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focuson areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
- R1 Therapeutics — R1 Therapeutics is developing innovative, category-defining therapeutics for patients with kidney disease.
We are a hands-on investment fund that operates exclusively in the Industry 4.0, energy and new materials sectors. Industrya is an initiative of the John Cockerill industrial group, which joins together the investment funds of SFPI-FPIM, SRIW-WING, NOSHAQ and LRM.
Show more...Investment focus
- Industry: Industrial, Manufacturing, Logistics
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: France, Belgium
Investor stats
- Total investments: 13
- Round size: Seed $1M–$4.2M; Series A $3.2M–$6.7M; Venture - Series Unknown $946k–$4M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
- PureNat — PureNat is a deep-tech economy company that has developed a brand new patented biomimetic material for the purification of air and sustainable air pollution control solutions.
- Get Your Way — Discover the future of assisted reality with Get Your Way's aRdent smart glasses. Perfect for SMEs looking for innovative solutions to improve their business
European Investment Bank operates as the lending institution of the European Union, offering loans, guarantees, and technical expertise to governments, businesses, and financial institutions. The organization focuses on areas such as climate action, digital transformation, housing development, and security-related initiatives. Its activities include funding large-scale infrastructure, supporting technology development, and facilitating access to capital for emerging and established enterprises. The bank also delivers advisory support to structure projects, improve investment readiness, and align initiatives with policy objectives.
Show more...Investment focus
- Industry: Energy, Biotechnology, Health Care
- Stage:Debt Financing, Post-IPO Debt, Venture - Series Unknown
- Geography: France, Germany, Italy
Investor stats
- Total investments: 600
- Round size: Post-IPO Debt $16M–$587M; Debt Financing $16M–$370M; Venture - Series Unknown $8.7M–$110M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- RougeTx — RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding.
- MedinCell — Join Medincell on a journey to transform global health with innovative therapies.
- Santander Brasil — Banco Santander in Brazil, its largest division in Latin America and one of the world's most important, accounting for 50%.
Opdorp Finance BVBA
Show more...Investment focus
- Industry: Software, Analytics, Life Science
- Stage:Series A
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- ONTOFORCE — ONTOFORCE helps life sciences organizations accelerate research and drug development for improved patient outcomes by unlocking hidden insights from data. Founded on semantic technology and an ontology-based knowledge graph, their flagship product, DISQOVER, is a data and knowledge platform developed specifically for the life sciences industry.DISQOVER seamlessly connects an organization’s internal, siloed data with licensed data and public data in one easy-to-use, customizable platform, enabling efficient data exploration and analysis. DISQOVER has over 10,000 users across the globe and is deployed by many leading pharmaceutical and biotechnology companies. Users include scientific researchers, bioinformaticians, data scientists, and many other roles. ONTOFORCE is headquartered in Ghent, Belgium and has a secondary office in the United States in Cambridge, Massachusetts. Learn more about ONTOFORCE at ontoforce.com and try DISQOVER at disqover.com.
Regeneron Ventures is a health care venture capital fund.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series B, Series A, Series C
- Geography: United States, Belgium
Investor stats
- Total investments: 17
- Round size: Series A $48M–$135M; Series B $40M–$175M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Infinimmune — Derived from human biology, engineered for human health. Infinimmune systematically surfaces and engineers the rare antibodies evolution has already proven in people and advances them into the clinic.
- City Therapeutics — City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference.
- Coultreon Biopharma — Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune disease. Our pipeline targets SIK3 to deliver transformative therapies where unmet need remains high.
Nausicaa Ventures is an early stage investment fund that finances early stage and early growth companies in and around Belgium.A multi-industry early stage venture capital fund Nausicaa Ventures is an early stage investment fund organisation focused on investment rounds between EUR 1 and 4 million.Nausicaa Ventures was created in 2009 bybringing together 35 private investors and selected institutional investors, such as the European Investment Fund or ING Bank, under the management of an experienced investment team. The target size of Nausicaa Ventures is upwards of EUR 20 million.Nausicaa Ventures combines the best of institutional venture capital groups and individual investors. It aims to cover the equity gap faced by most, promising early stage companies on their path towards profitable growth. Nausicaa Ventures has the resources, knowledge, experience and agility to respond to the financial and management needs of those companies, and to work side-by-side with them towards the achievement of successful exits.
Show more...Investment focus
- Industry: Software, CRM, Big Data
- Stage:Series B, Series C, Venture - Series Unknown
- Geography: Belgium
Investor stats
- Total investments: 4
- Round size: Series B $9.4M–$10M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- NGDATA — NGDATA is the consumer intelligence management solutions company that empowers enterprises seeking greater customer lifetime value to drive continuous, actionable insights to enable sales and increase customer loyalty.The company does this through its unique combination of Big Data management and machine learning technologies in a singleintegrated solution.Recently named one of Bank Systems and Technology Magazine’s “Top 7 Big Data Players to Watch,” NGDATA is headquartered in Ghent, Belgium with offices in New York City and San Francisco. The company provides solutions to data-driven sectors such as financial services, retail and media/publishing.
- Ovizio — Ovizio develops digital holographic interferometric microscopy products. It builds 4D microscopic imaging devices and software based on digital holographic microscopy. Ovizio offers oLine 4D, a research and development, and diagnostic desktop device that is used without specific sample preparation, as well as with automatic compensation ofscratches or distortions on the sample support; iLine 4D, a multipurpose device for applications, such as inline or online flow monitoring or direct monitoring of cell cultures in bioreactors; and OsOne software for visualization, analysis, and archiving of images captured by the imaging devices. It also provides ILine F, a device that captures suspension cell culture process in real time; iLine M, an instrument that monitors cell confluence in multi layer vessels; iLine S, an equipment that monitors reproducibility of fragile cell; and QMod, a holographic and fluorescene microscopy. Scientists in the areas of pharmaceutical and biotech research and development use the products of Ovizio. Philip Mathuis and Serge Jooris founded it in 2009, with its headquarters in Brussels in Belgium.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series A, Series C
- Geography: United States, France, Switzerland
Investor stats
- Total investments: 227
- Round size: Series A $7.3M–$100M; Series B $15M–$150M; Series C $15M–$94M
- Lead/follow: 30% lead, 70% follow
- Last fund: Likely actively investing — fresh fund, raised $500M in 2024
Portfolio highlights
- Cebix — Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.
- Aerie Pharmaceuticals — Aerie Pharmaceuticals, a leading ophthalmic pharmaceuticals company conducting R&D of products for treating patients with glaucoma and other eye diseases.
- Lisata Therapeutics — Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.
Show more...Investment focus
- Industry: Biotechnology, Medical, Pharmaceutical
- Stage:Series A, Venture - Series Unknown, Seed
- Geography: Belgium, Japan, France
Investor stats
- Total investments: 22
- Round size: Seed $2.9M–$3.2M; Series A $6.1M–$84M; Venture - Series Unknown $1.3M–$20M
- Lead/follow: 68% lead, 32% follow
- Last fund: Likely still investing — raised $57M in 2022
Portfolio highlights
- Bioxodes — Bioxodes is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events without hemorrhagic risk.
- Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
- Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.
Fonds Vives II (University of Louvain, UCL)
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: Belgium, United States
Investor stats
- Total investments: 5
- Round size: Series A $9.9M–$16M; Series B $6.6M–$75M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Virovet — Antiviral drugs and thermostable vaccines for livestock
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- ITeos Therapeutics — iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for cancer patients.
Balyasny is a multi-strategy asset management firm. Our goal is to provide consistent, uncorrelated returns in all market environments.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Biopharma
- Stage:Post-IPO Equity, Series A, Series D
- Geography: United States, China, Latvia
Investor stats
- Total investments: 54
- Round size: Series A $6.1M–$179M; Series D $35M–$225M; Post-IPO Equity $35M–$197M
- Lead/follow: 9% lead, 91% follow
- Last fund: Likely actively investing — fresh fund, raised $2.5M in 2026
Portfolio highlights
- Jasper Therapeutics — Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant.
- Soufflé Therapeutics — Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology.
- Werewolf Therapeutics — Developing transformative conditionally activated proinflammatory immune modulating medicines to unleash a powerful attack on cancer.
Flanders Future Techfund operates as an investment firm.
Show more...Investment focus
- Industry: Medical, Biotechnology, Clinical Trials
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Belgium, The Netherlands
Investor stats
- Total investments: 7
- Round size: Seed $2.7M–$30M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- EDGX — EDGX, founded in 2023 in Ghent, is a Belgian Space Tech company developing high-speed edge computing units for satellites. Its NVIDIA-powered Sterna Computer and SpaceFeather software enable real-time, AI-driven on-orbit data processing for applications in communication, Earth observation, and intelligence.
- Flindr Therapeutics — Immagene develops personalized cancer immunotherapies to fight multiple cancer type.
- Clouds of care — Increasing your probability of success through the adoption of meaningful endpoints, starting from electrophysiology.
Ifoghas Investments operates as an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Series A
- Geography: Belgium
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Nivelinvest is a venture capital firm based in Belgium that finances seed stage investments of Small and Medium Enterprises.
Show more...Investment focus
- Industry: Biotechnology, iOS, Energy
- Stage:Series A, Seed, Series B
- Geography: Belgium, United States
Investor stats
- Total investments: 6
- Round size: Series A $6.6M–$32M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- e-peas — Discover e-peas, pioneer of the Ambient IoT concept since 2014, which offers the most efficient energy harvesting pmics on the market to make your devices more energy self-sufficient: AEMs.
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases. Its main offerings include pioneering scientific breakthroughs and expanding access to their medicines, with the ultimate goal of preventing and curing disease.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Corporate Round, Series A, Series C
- Geography: United States, Denmark, Canada
Investor stats
- Total investments: 21
- Round size: Series A $5M–$17M; Series C $16M–$57M
- Lead/follow: 48% lead, 52% follow
Portfolio highlights
- Cellular Intelligence — Somite.ai is on a mission to transform the lives of millions of people by leveraging AI to produce human tissue for cell-based therapies.
- Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
- Proton HeartPet — Proton HeartPet is the company in the field of pet intelligent medical care.
invest.bw is a venture capital firm.
Show more...Investment focus
- Industry: Biotechnology, Electronics, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: Belgium, United States
Investor stats
- Total investments: 10
- Round size: Seed $2.9M–$43M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- e-peas — Discover e-peas, pioneer of the Ambient IoT concept since 2014, which offers the most efficient energy harvesting pmics on the market to make your devices more energy self-sufficient: AEMs.
- neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Epimède SA
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series B, Series C, Series D
- Geography: Belgium, The Netherlands
Investor stats
- Total investments: 5
- Round size: Series B $12M–$26M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Imcyse — Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on theadministration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.
- Ncardia — At Ncardia, we believe that human stem cell technology will help get better therapies to patients faster.
- Endo Tools Therapeutics — Endo Tools Therapeutics is dedicated to the development of innovative devices that provide therapeutic interventions for gastric conditions
Life Science VC funding in Belgium at a glance
Stats across 50 deals from 71 investors.
Access all 71 VC funds in Belgium Life Science startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Life Science VC Funds in Belgium investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 71 VC funds investing in Belgium Life Science startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!